menu
    • menu
    [{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Mustang Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"MB-207","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirion Biotech \/ Mustang Bio","highestDevelopmentStatusID":"7","companyTruncated":"Sirion Biotech \/ Mustang Bio"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Allogeneic CAR T-cells","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sirion Biotech \/ Cellectis","highestDevelopmentStatusID":"3","companyTruncated":"Sirion Biotech \/ Cellectis"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AAV capsid-gene therapy","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Sirion Biotech \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Sirion Biotech \/ Sanofi"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"PerkinElmer","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sirion Biotech \/ PerkinElmer","highestDevelopmentStatusID":"4","companyTruncated":"Sirion Biotech \/ PerkinElmer"}]

    Find Clinical Drug Pipeline Developments & Deals by Sirion Biotech

    Menu

    Sirion Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sirion Biotech

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sirion Biotech

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-based Gene Therapy

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : PerkinElmer

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PerkinElmer’s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors ...

                            Details : The collaboration combines SIRION’s adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy and expertise in viral vector development and production with CRG’s deep knowledge of genetic regulatory mechanisms.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 16, 2022

                            Lead Product(s) : AAV-based Gene Therapy

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : PerkinElmer

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sirion Biotech

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sirion Biotech

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV capsid-gene therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Ass...

                            Details : Sanofi, together with SIRION will develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 23, 2021

                            Lead Product(s) : AAV capsid-gene therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sirion Biotech

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sirion Biotech

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic CAR T-cells

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Cellectis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SIRION Biotech GmbH Licensed Its LentiBOOST™ Transduction Technology to Cellectis

                            Details : Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 07, 2021

                            Lead Product(s) : Allogeneic CAR T-cells

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Cellectis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sirion Biotech

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sirion Biotech

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MB-207

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Mustang Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mustang Bio Licenses LentiBOOST™ Technology from SIRION Biotech

                            Details : Mustang has acquired rights to SIRION’s LentiBOOST™ technology for the development of MB-207, Mustang’s lentiviral gene therapy for the treatment of patients with X-linked severe combined immunodeficiency.

                            Brand Name : MB-207

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 06, 2020

                            Lead Product(s) : MB-207

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Mustang Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth